Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer
Authors
Keywords
-
Journal
DRUGS
Volume 71, Issue 11, Pages 1385-1396
Publisher
Springer Nature
Online
2011-08-05
DOI
10.2165/11592590-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chemical and Clinical Development of Darinaparsin, a Novel Organic Arsenic Derivative
- (2012) Alfonso Quintas-Cardama et al. Anti-Cancer Agents in Medicinal Chemistry
- Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies
- (2011) F. R. Kona et al. CURRENT CANCER DRUG TARGETS
- Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
- (2011) B. Cvek CURRENT CANCER DRUG TARGETS
- Overcoming Taxane and Anthracycline Resistance
- (2010) Amelia Zelnak Breast Journal
- Redox platforms in cancer drug discovery and development
- (2010) Kenneth D Tew et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study
- (2010) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
- (2009) Georg T. Wondrak ANTIOXIDANTS & REDOX SIGNALING
- Glutathione dysregulation and the etiology and progression of human diseases
- (2009) Nazzareno Ballatori et al. BIOLOGICAL CHEMISTRY
- Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome
- (2009) A. Raza et al. BLOOD
- A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
- (2009) Steven J. Cohen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase
- (2009) Frederick H. Hausheer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
- (2009) I. Vergote et al. EUROPEAN JOURNAL OF CANCER
- Darinaparsin: a novel organic arsenical with promising anticancer activity
- (2009) Koren K Mann et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma
- (2009) Jennifer Wu et al. INVESTIGATIONAL NEW DRUGS
- A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer
- (2009) Stacy Moulder et al. INVESTIGATIONAL NEW DRUGS
- Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer
- (2009) Lecia V. Sequist et al. Journal of Thoracic Oncology
- Redox Regulation of Cell Survival
- (2008) Dunyaporn Trachootham et al. ANTIOXIDANTS & REDOX SIGNALING
- Mechanisms of ROS modulated cell survival during carcinogenesis
- (2008) J.S. Clerkin et al. CANCER LETTERS
- Dual Actions Involved in Arsenite-Induced Oxidative DNA Damage
- (2008) Xu-Jun Qin et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Motexafin Gadolinium for the Treatment of Metastatic Renal Cell Carcinoma: Phase II Study Results
- (2008) Robert J. Amato et al. Clinical Genitourinary Cancer
- NOV-002, a mimetic of glutathione disulfide
- (2008) Danyelle M Townsend et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial
- (2008) Minesh P. Mehta et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Further insights into the mechanism of the reaction of activated bleomycin with DNA
- (2008) M. S. Chow et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-induced cytotoxic effects in neuroblastoma
- (2007) Barbara Marengo et al. FREE RADICAL BIOLOGY AND MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started